Erratum: Interferon-free strategies without a nucleoside/nucleotide analogue (Seminars in Liver Disease (2014) 34:1 (52-54) DOI: 10.1055/s-0034-1371010);Interferon-free strategies without a Nucleoside/nucleotide analogue

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 47-57

  Welzel, Tania Mara ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

direct acting antiviral agents; host targeting agents; interferon free HCV treatment; non nucleoside polymerase inhibitors; NS3 4A protease inhibitors; NS5A inhibitors

Indexed keywords

ABT 450; ACH 1625; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; BZF 961; DACLATASVIR; DANOPREVIR; DASABUVIR; DELDEPREVIR; DIRECT ACTING ANTIVIRAL AGENT; FALDAPREVIR; GS 9256; HOST TARGETING AGENT; LEDIPASVIR; MK 5172; NARLAPREVIR; NON NUCLEOSIDE POLYMERASE INHIBITOR; NONSTRUCTURAL PROTEIN 3 4A PROTEINASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; RIBAVIRIN; RO 5466731; SAMATASVIR; SERINE PROTEINASE INHIBITOR; SETROBUVIR; SIMEPREVIR; SOVAPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VEDROPREVIR; CARRIER PROTEIN; INTERFERON; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; NUCLEOSIDE; NUCLEOTIDE; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MOLECULAR TARGETED THERAPY; NUCLEOSIDES; NUCLEOTIDES; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84899720590     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1375967     Document Type: Erratum

References (82)

1. Lohmann V., Körner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science: 1999; 285 5424 110 113
2. Lohmann V., Bartenschlager R. On the history of hepatitis C virus cell culture systems. J Med Chem: 2013;; In press
3. Bartenschlager R., Lohmann V., Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol: 2013; 11 7 482 496
4. Lange C. M., Jacobson I. M., Rice C. M., Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO. Mol Med: 2013;; In press
5. Manns M. P., von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov: 2013; 12 8 595 610
6. Mohd Hanafiah K., Groeger J., Flaxman A. D., Wiersma S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology: 2013; 57 4 1333 1342
7. Smith B. D., Morgan R. L., Beckett G. A., Falck-Ytter Y., Holtzman D., Ward J. W. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med: 2012; 157 11 817 822
8. Moyer V. A.; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med: 2013; 159 5 349 357
9. Thomas D. L. Global control of hepatitis C: where challenge meets opportunity. Nat Med: 2013; 19 7 850 858
10. Jacobson I. M., McHutchison J. G., Dusheiko G., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 25 2405 2416
11. Zeuzem S., Andreone P., Pol S., et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med: 2011; 364 25 2417 2428
12. Poordad F., McCone J. Jr, Bacon B. R., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1195 1206
13. Bacon B. R., Gordon S. C., Lawitz E., et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1207 1217
14. Lok A. S., Gardiner D. F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med: 2012; 366 3 216 224
15. Simmonds P., Bukh J., Combet C., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology: 2005; 42 4 962 973
16. Moradpour D., Penin F., Rice C. M. Replication of hepatitis C virus. Nat Rev Microbiol: 2007; 5 6 453 463
17. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology: 2010; 138 2 447 462
18. Vermehren J., Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol: 2012; 26 4 487 503
19. Gerber L., Welzel T. M., Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int: 2013; 33 01 85 92
20. Pockros P. J. Nucleoside/nucleotide analogue polymerase inhibitors in development. Clin Liver Dis: 2013; 17 1 105 110
21. Feld J. IFN-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis: 2014; 34 1 37 46
22. Pockros P. J. Non-nucleoside analogue polymerase inhibitors in development. Clin Liver Dis: 2013; 17 1 123 128
23. Ciesek S., von Hahn T., Manns M. P. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis: 2011; 15 3 597 609
24. Clark V. C., Peter J. A., Nelson D. R. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int: 2013; 33 01 80 84
25. Summa V., Ludmerer S. W., McCauley J. A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother: 2012; 56 8 4161 4167
26. Huang M., Podos S., Patel D., et al. ACH-2684: HCV NS3 protease inhibitor with a potent activity against multiple genotypes and known resistant variants. Hepatology: 2010; 52 (S1): 1204A
27. Coburn C. A., Meinke P. T., Chang W., et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem: 2013; 8 12 1930 1940 [Epub ahead of print]
28. Achillion. ACH-3102 HCV NS5A inhibitor. Available at: http://www.achillion.com/ACH-3102. Accessed November 18, 2013
29. Zeuzem S., Soriano V., Asselah T., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med: 2013; 369 7 630 639
30. Dufour J. F., Buti M., Soriano V., et al. Interferon-Free Treatment with Faldaprevir, Deleobuvir (BI 207127) and RBV in SOUND-C3: 95% SVR12 in HCV-GT 1b. Hepatology: 2013; 58 4 139A [1102]
31. ClinicalTrials.gov. IFN-free combination therapy in HCV-infected patients treatment-naive:HCVerso1. Available at: http://www.clinicaltrials.gov/ct2/ results?term=HCVerso1&Search=Search. Accessed November 18, 2013
32. ClinicalTrials.gov. Phase 3 study of BI 207127 in combination with faldaprevir and ribavirin for treatment of patients with hepatitis C infection, including patients who are not eligible to receive peginterferon: HCVerso2. Available at: http://www.clinicaltrials.gov/ct2/results?term= HCVerso2&Search=Search. Accessed November 18, 2013
33. ClinicalTrials.gov. BI 207127 / faldaprevir combination therapy in hepatic impairment (Child-Pugh B) patients with genotype 1b chronic hepatitis C infection: HCVerso3. Available at: http://www.clinicaltrials.gov/ct2/results? term=hcverso3&Search=Search. Accessed November 18, 2013
34. Lawitz E., Poordad F., Kowdley K. V., et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol: 2013; 59 1 18 23
35. Poordad F., Lawitz E., Kowdley K. V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med: 2013; 368 1 45 53
36. Kowdley K. V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med: 2014; 16; 370 3 222 232
37. Jacobsen I. M., Sulkowski M. S., Gane E. J., et al. VX-222, Telaprevir, and ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C: results from the ZENITH study interferon-free regimen. Hepatology: 2012; 56 4 87A [231]
38. Jensen D. M., Brunda M., Elston R., et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: interim SVR4 results from the ANNAPURNA study. Hepatology: 2013; 58 4 139A [1098]
39. ClinicalTrials.gov. A study to evaluate the safety, tolerability, and effectiveness of a 12-week combination therapy of TMC647055 and TMC435 with and without GSK23336805 with a pharmacokinetic enhancer with and without ribavirin in patients infected with chronic genotype 1 hepatitis C virus. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01724086?term=tmc435&rank=26. Accessed November 18, 2013
40. Suzuki Y., Ikeda K., Suzuki F., et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol: 2013; 58 4 655 662
41. Chayama K., Takahashi S., Toyota J., et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology: 2012; 55 3 742 748
42. Lok A. S., Gardiner D. F., Hézode C., Lawitz E. J., et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol: 2014; Mar; 60 3 490 499
43. Bronowicki J. P., Pol S., Thuluvath P. J., et al. BMS-650032, an NS3 inhibitor, in combination with peginterferon alfa-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection. [abstract] J Hepatol: 2011; 54 S472. [1195]
44. Chayama K., Suzuki Y., Ikeda K., et al. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV Genotype 1b: results from a phase 3 trial. Hepatology: 2013; 58 4 86A [211]
45. ClinicalTrials.gov. Phase III Hallmark DUAL: ASVb+b DCV (nulls/partials, intolerants/ineligibles. naives). Available at: http://www.clinicaltrials.gov/ ct2/show/NCT01581203?term=hallmark+dual&rank=1. Accessed November 18, 2013
46. ClinicalTrials.gov. Study of daclatasvir and TMC435 for subjects with genotype 1 chronic hepatitis C. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT01628692?term=tmc435+daclatasvir&rank=1. Accessed on November 18, 2013
47. Lawitz E., Hezode C., Varunok P., et al. Interferon- and Ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment naive patients and prior null responders. Hepatology: 2013; 58 4 62A [75]
48. Lawitz E., Vierling J. M., Murillo A., et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742. b ±b RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study. Hepatology: 2013; 58 4 62A [76]
49. Achillion. Achillion provides update on sovaprevir development program. Available at: http://ir.achillion.com/releasedetail.cfm?ReleaseID=774834. Accessed November 18, 2013
50. Lalezari J. P., Holland L., Glutzer E., et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection. Hepatology: 2013; 58 4 [LB-20]
51. Everson G. T., Sims K. D., Rodriguez-Torres M., et al. Efficacy of an Interferon- and Ribavirin-free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-naïve Patients with HCV Genotype 1 Infection. Gastroenterology: 2014; 146 2 420 429
52. Everson G. T., Sims K. D., Thuluvath P. J., et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chonic HCV genotype 1 infection. Hepatology: 2013; 58 4 [LB-1]
53. Cohen D. E., Xie W., Larsen L., et al. Safety of ribavirin containing regimens of ABT-450/r, ABT-333, and ABT-267 for the treatment of HCV genotype 1 infection and efficacy in subjects with ribavirin dose reductions. Hepatology: 2013; 58 4 140A [1118]
54. ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection. Available at: http://www.clinicaltrials.gov/ct2/results?term=sapphire- I&Search=Search. Accessed November 18, 2013
55. ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in treatment experienced adults. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT01715415?term=sapphire-II&rank=1. Accessed November 18, 2013
56. ClinicalTrials.gov. A study to evaluate the safety and effect of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis (TURQUOISE-II). Available at: http://www.clinicaltrials. gov/ct2/show/NCT01704755?term=turquoise&rank=1. Accessed November 18, 2013
57. ClinicalTrials.gov. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C. Available at: http://abbvie.mediaroom.com/index.php?year=2013&s=20295. Accessed December 27, 2013
58. ClinicalTrials.gov. A study to evaluate the safety and effect of the experimental drugs ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in people with chronic hepatitis C (PEARL-II). Available at: http://www. clinicaltrials.gov/ct2/show/NCT01674725?term=PEARL-II&rank=1. Accessed November 18, 2013
59. ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in adults with genotype 1b infection (PEARL-III). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01767116?term=Pearl-III&rank=1. Accessed November 18, 2013
60. ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in adults with genotype 1a infection. Available at: http://www.clinicaltrials.gov/ ct2/results?term=Pearl-IV&Search=Search. Accessed November 18, 2013
61. Toyota J., Ozeki I., Karino Y., et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat: 2013; 20 3 167 173
62. Gane E. J., Ari Z. B., Mollison L., et al. Efficacy and safety of an interferon-free regimen of MK-5172 + Ribavirin for 12 weeks or 24 weeks in treatment naive, non cirrhotic subjects with HCV GT1 infection: the C-Spirit study. Hepatology: 2013; 58 4 140A [1110]
63. Baugh J. M., Garcia-Rivera J. A., Gallay P. A. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res: 2013; 100 2 555 561
64. Zeisel M. B., Lupberger J., Fofana I., Baumert T. F. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol: 2013; 58 2 375 384
65. Meuleman P., Hesselgesser J., Paulson M., et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology: 2008; 48 6 1761 1768
66. Meuleman P., Catanese M. T., Verhoye L., et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology: 2012; 55 2 364 372
67. Lacek K., Vercauteren K., Grzyb K., et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol: 2012; 57 1 17 23
68. Lupberger J., Zeisel M. B., Xiao F., et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med: 2011; 17 5 589 595
69. Sainz B. Jr, Barretto N., Martin D. N., et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med: 2012; 18 2 281 285
70. Sulkowski M. S., Kang M., Matining R., et al. AIDS Clinical Trials Group A5277 Protocol Team. Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study. J Infect Dis: 2014; Mar; 209 5 658 667
71. Chen K., Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet: 2007; 8 2 93 103
72. Thibault P. A., Wilson J. A. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res: 2013; 75 48 59
73. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
74. Paeshuyse J., Kaul A., De Clercq E., et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology: 2006; 43 4 761 770
75. Chatterji U., Bobardt M., Selvarajah S., et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem: 2009; 284 25 16998 17005
76. Coelmont L., Kaptein S., Paeshuyse J., et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother: 2009; 53 3 967 976
77. Tiongyip C., Jones C. T., Tang Y., et al. Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals. Abstract presented at: The Sixth International Workshop on Hepatitis C, Resistance and New Compounds; June 23-24, 2011; Cambridge, MA
78. ClinicalTrials.gov. Pharmacokinetics, pharmacodynamics and safety of DEB025 plus ribavirin in chronic hepatitis C genotype 2 and 3 treatment naïve patients. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01970904?term=cdeb025A2222&rank=1. Accessed November 18, 2013
79. Pawlotsky J. M., Sarin S. K., Foster G., et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study. J Hepatol: 2012; 56 2 S553 [1405]
80. Chatterji U., Wong K. A., Zhong W., et al. The Combination of Alisporivir with an NS5A Inhibitor Provides Additive to Synergistic Antiviral Activity, no Cross-Resistance and a High Barrier to HCV Resistance. Hepatology: 2013; 58 4 62A [74]
81. Hopkins S., DiMassimo B., Rusnak P., et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol: 2012; 57 1 47 54
82. Owens CM, Rhodin MHJ, Polemeropoulos A, et al. Cyclophilin inhibitor EDP-546 is a potential cornerstone drug for use in combination with NS5A and protease inhibitors due to its high barrier to HCV resistance. J Hepatol 2013;58(1):S493.